Sector
PharmaceuticalsOpen
₹427.5Prev. Close
₹426.15Turnover(Lac.)
₹683.9Day's High
₹432.15Day's Low
₹413.0552 Week's High
₹658.8552 Week's Low
₹366.25Book Value
₹142.66Face Value
₹1Mkt Cap (₹ Cr.)
6,929.2P/E
25.37EPS
16.81Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 16.28 | 16.59 | 16.88 | 16.88 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,080.92 | 1,964.15 | 1,931.8 | 1,705.28 |
Net Worth | 2,097.2 | 1,980.74 | 1,948.68 | 1,722.16 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 1,325.44 | 1,331.09 | 1,062.19 | 1,008.91 |
yoy growth (%) | -0.42 | 25.31 | 5.28 | 2.23 |
Raw materials | -412.05 | -424.53 | -349.97 | -336.73 |
As % of sales | 31.08 | 31.89 | 32.94 | 33.37 |
Employee costs | -294.31 | -276.18 | -215.46 | -189.93 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 380.45 | 325.45 | 233.9 | 255.66 |
Depreciation | -37.62 | -37.36 | -35.03 | -34.52 |
Tax paid | -85.96 | -78.68 | -65.59 | -62.71 |
Working capital | 22.62 | 78.25 | 14.4 | 16.61 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.42 | 25.31 | 5.28 | 2.23 |
Op profit growth | 14.36 | 29.42 | -9.44 | 6.6 |
EBIT growth | 16.71 | 39.76 | -8.46 | 10.17 |
Net profit growth | 19.33 | 46.61 | -10.02 | 10.75 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 1,942.94 | 1,783.75 | 1,527.92 | 1,333.2 | 1,344.19 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,942.94 | 1,783.75 | 1,527.92 | 1,333.2 | 1,344.19 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 101.63 | 49.86 | 76.09 | 97.03 | 68.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,787.4 | 137.43 | 4,32,960 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,012.5 | 79.59 | 1,65,003.32 | 594 | 0.48 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,525.9 | 26.92 | 1,25,285.64 | 1,438.15 | 0.84 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,238.9 | 61.67 | 1,12,502.67 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,557.5 | 55.53 | 1,07,385.94 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Mohan A Chandavarkar
Executive Director
Ashok A Chandavarkar
Joint Managing Director
Nandan M Chandavarkar
Executive Director & CEO
Ameya A Chandavarkar
Chairman Emeritus
Ramdas A Chandavarkar
Company Sec. & Compli. Officer
Varsharani Katre
Non Executive Director
Nomita R Chandavarkar
Chairman & Independent Directo
Uday Kumar Gurkar
Independent Director
Mahesh Bijlani
Independent Director
Vijay Maniar
Independent Director
Swati S Mayekar
Independent Director
Vijay N Bhatt
Independent Director
Charuta Nityanath Mandke
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by FDC Ltd
Summary
FDC Limited is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company is a prominent player in the Indian pharmaceutical industry, renowned for its expertise in developing specialised formulations. It leads the market in sectors such as Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies. It has established a global footprint in both domesticand international market, standing as a beacon of excellence in pharmaceutical and consumer healthcare industry. Promoted as a partnership firm in 1936 by the Late Anand Chandravarkar to import pharmaceutical dosage forms, specialised infant foods and surgical goods, FDC Limited was established on September 23, 1940. It set up a formulation unit at Jogeshwari, Bombay in 1949.FDC has 2 wholly owned subsidiaries namely FDC Inc., USA and FDC International Ltd, UK and 1 Joint Venture business, namely Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. at South Africa as on 31 March 2019.FDC manufactures Electral, oral rehydration salt (ORS), being a leader in this segment. FDC manufactures bulk drugs, formulations and food products. The plant at Roha manufactures pharma dosage forms, food products and bulk drugs for the anti-rheumatic, anti-asthmatic, opthalmic and ENT segments. The company part financed its technical upgradation/modernisation/backward integration/e
Read More
The FDC Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹425.6 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of FDC Ltd is ₹6929.20 Cr. as of 25 Apr ‘25
The PE and PB ratios of FDC Ltd is 25.37 and 3.04 as of 25 Apr ‘25
The 52-week high/low is the highest and lowest price at which a FDC Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of FDC Ltd is ₹366.25 and ₹658.85 as of 25 Apr ‘25
FDC Ltd's CAGR for 5 Years at 10.35%, 3 Years at 15.54%, 1 Year at -5.85%, 6 Month at -17.64%, 3 Month at -9.50% and 1 Month at 2.59%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.